Analysed MBX BIOSCIENCES INC (MBX:NASDAQ) News Sources
MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City
26-05-2026
yahoo.com
MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at ENDO 2026
01-06-2026
yahoo.com
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
12-06-2026
yahoo.com
MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)
12-06-2026
advfn.com
How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?
15-06-2026
yahoo.com
Post-Bariatric Hypoglycemia Market to Register Stunning Growth at a 16.4% CAGR Through 2036 Owing to the Emergence of Novel Drug Classes Such as GLP-1 Receptor Antagonists, SGLT1 Inhibitors, CRH Inhibitors, and SSTR5 Agonists | DelveInsight
07-07-2026
yahoo.com
MBX Biosciences Announces Executive Leadership Transition to Support the Company’s Next Phase of Growth
13-07-2026
yahoo.com
What is the current price of MBX BIOSCIENCES INC (MBX:NASDAQ)?
The current price of MBX BIOSCIENCES INC (MBX:NASDAQ) is $59.29.
MBX BIOSCIENCES INC (MBX:NASDAQ) absolute price change since previous trading day?
The absolute price change of MBX BIOSCIENCES INC (MBX:NASDAQ) since the previous trading day is $-1.385.
MBX BIOSCIENCES INC (MBX:NASDAQ) percentage price change since previous trading day?
The percentage price change of MBX BIOSCIENCES INC (MBX:NASDAQ) since the previous trading day is -2.2827%.
What is the most recent average sentiment score for MBX BIOSCIENCES INC (MBX:NASDAQ)?
The most recent average sentiment score for MBX BIOSCIENCES INC (MBX:NASDAQ) is 76 out of 100.
What is the most recent average sentiment for MBX BIOSCIENCES INC (MBX:NASDAQ)?
The most recent sentiment for MBX BIOSCIENCES INC (MBX:NASDAQ) is .
SEC-8K** Filing Available For MBX BIOSCIENCES INC (MBX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.